16 completed, 8 terminated, 1 recruiting, 1 withdrawn. 13 Phase 2, 8 Phase 1, 7 Phase 3, 4 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 9, Terminated 4 |
| Phase 1 | 8 | Completed 5, Terminated 3 |
| Phase 3 | 7 | Completed 5, Terminated 2 |
| Not applicable | 4 | Completed 3, Withdrawn 1 |
Follow mecasermin: new trials by email Literature Review of mecasermin trials Research Report on mecasermin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency Increlex - Short Stature | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 7 | 2015-12-21 | 2024-02-28 |
| A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder IGF-1, Placebo/saline - Autism Spectrum Disorder | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 3 | 2014-05-01 | 2024-02-08 |
| Treatment of Rett Syndrome With Recombinant Human IGF-1 Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo - Rett Syndrome | Phase 2 | Completed | Boston Children's Hospital | 30 | 2013-01-01 | 2018-03-26 |
| Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome) Insulin-Like Growth Factor-1 (IGF-1), Normal saline - 22q13 Deletion Syndrome, Phelan-McDermid Syndrome | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 19 | 2012-02-01 | 2022-05-12 |
| Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack mecasermin, 0.9% sodium chloride injection - Heart Failure, Myocardial Infarction | Phase 1 / Phase 2 | Completed | University College Cork | 47 | 2011-10-01 | 2017-03-30 |
| IGF-1 and Bone Loss in Women With Anorexia Nervosa rhIGF-1, Risedronate, Placebo - Anorexia Nervosa, Osteopenia | Not applicable | Completed | Massachusetts General Hospital | 148 | 2011-10-01 | 2020-07-17 |
| IGF-I Stimulation of Collagen Synthesis in Ehlers-Danlos Patients mecasermin, Saline - Ehlers-Danlos Syndrome, Classic | Not applicable | Completed | Bispebjerg Hospital | 15 | 2011-09-01 | 2012-11-20 |
| Effects of IGF-I in HIV Metabolic Disease mecasermin, Placebo control - HIV Lipodystrophy | Phase 1 | Terminated | University of Texas Southwestern Medical Center | 16 | 2011-06-01 | 2016-03-23 |
| Increlex Treatment of Children With Chronic Liver Disease and Short Stature Increlex - Growth Failure, Chronic Liver Disease | Not applicable | Withdrawn | University of California, Los Angeles | 2011-06-01 | 2026-04-14 | |
| IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations Increlex, 0.9% Saline - Type 1 Diabetes Mellitus | Not applicable | Completed | Peter Bang | 8 | 2011-04-01 | 2012-04-30 |
| Effects of Anorexia Nervosa on Peak Bone Mass RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol - Anorexia Nervosa | Phase 3 | Completed | Massachusetts General Hospital | 75 | 2011-02-01 | 2021-07-13 |
| Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) rhIGF-1 - Rett Syndrome | Phase 1 | Completed | Boston Children's Hospital | 12 | 2010-12-01 | 2017-06-22 |
| Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy IGF-1 - Duchenne Muscular Dystrophy | Phase 1 / Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 44 | 2010-11-01 | 2021-01-20 |
| Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT) NutropinAq (GH) and Increlex (IGF-I), NutropinAq and placebo - Diabetes | Phase 3 | Completed | Karolinska University Hospital | 14 | 2009-10-01 | 2015-04-07 |
| Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD). Increlex® - IGF1 Deficiency | Recruiting | Esteve Pharmaceuticals, S.A. | 500 | 2008-12-09 | 2026-02-06 | |
| Effect of Increlex® on Children With Crohn Disease rhIGF (Increlex) - Crohn Disease | Phase 2 / Phase 3 | Terminated | Nationwide Children's Hospital | 3 | 2008-10-01 | 2018-03-02 |
| IGF-1 Therapy in Patients With Cystic Fibrosis recombinant human IGF-1, Placebo - Cystic Fibrosis | Phase 1 | Terminated | Stony Brook University | 15 | 2008-06-01 | 2013-01-28 |
| rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]) - Insulin-like Growth Factor-1 Deficiency | Phase 2 | Terminated | Ipsen | 106 | 2007-12-01 | 2023-03-30 |
| Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 Increlex - Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID) | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 6 | 2007-06-01 | 2015-07-03 |
| Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents RhIGF-1 - Anorexia Nervosa | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 16 | 2007-03-01 | 2021-11-18 |
Showing 20 of 26. Sign in to see all of them.
Anorexia Nervosa (3) · Dwarfism (3) · Growth Disorders (3) · Autism Spectrum Disorder (2) · Failure to Thrive (2) · Insulin-Like Growth Factor I Deficiency (2) · Rett Syndrome (2) · Autistic Disorder (1) · Body Weight (1) · Bone Diseases, Metabolic (1) · Collagen Diseases (1) · Crohn Disease (1) · Cystic Fibrosis (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1)
Ipsen (6) · Massachusetts General Hospital (3) · Boston Children's Hospital (2) · Children's Hospital Medical Center, Cincinnati (2) · Icahn School of Medicine at Mount Sinai (2) · Bispebjerg Hospital (1) · Esteve Pharmaceuticals, S.A. (1) · Karolinska University Hospital (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Nationwide Children's Hospital (1) · Peter Bang (1) · Stony Brook University (1) · University College Cork (1) · University of California, Los Angeles (1)
United States (19) · Sweden (3) · France (2) · Austria (1) · Denmark (1) · French Guiana (1) · Germany (1) · Ireland (1) · Italy (1) · Martinique (1) · Netherlands (1) · Poland (1) · Spain (1) · United Kingdom (1)
Alexander Kolevzon, MD (2) · Mustafa Sahin, MD, PhD (2) · Anne Klibanski, MD (1) · Charlotte Hoeybye, MD (1) · Dana S. Hardin, MD (1) · Erinne Meenaghan, NP (1) · Gajanathan Muthuvel, MD (1) · Karen Miller, MD (1) · Madhu Misra (1) · Madhusmita Misra, MD, MPH (1) · Meilan Rutter, MD (1)
PMID 17192294, PMID 25685306, PMID 29029190, PMID 33434161, PMID 35250870, PMID 35395866, PMID 36646053, PMID 37579214, PMID 37811711, PMID 40351246, PMID 40626687
2019 (4), R34MH100276 (1)